Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...

(RTTNews) - Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary endpoint by demonstrating a statistically significant ...

Please provide your email address to receive an email when new articles are posted on . In the STEP trials, a higher proportion of adults receiving semaglutide stopped antihypertensive or ...

Credit: Getty Images Until semaglutide, weight loss of 15% to avoid obesity-related complications was only achieved through bariatric surgery. In clinical trials, semaglutide proved to be superior to ...